- Market advances adoption of ready-to-use containers
- Improved operational efficiency in pharmaceutical
manufacturing processes
- Increased patient safety with high-quality sterile primary
packaging
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries,
together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG
& Co. KGaA (MDAX: 1SXP), announced today that they have entered
into a strategic industry alliance ("Alliance for RTU") to support
market adoption of Ready-to-Use (RTU) vials and cartridges.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240926050295/en/
Stevanato Group, Gerresheimer &
SCHOTT Pharma join forces in the 'Alliance for RTU' (Photo:
Business Wire)
The Alliance for RTU aims to share with pharmaceutical
companies, CMOs and CDMOs expertise and technical knowledge in
high-quality sterile primary packaging, specifically ready-to-fill
vials and cartridges, highlighting RTU configurations' advantages
over conventional bulk packaging.
Reduced risks and lower total cost of ownership
Traditional fill&finish processes present several
operational risks and require increased efficiency. By adopting an
industrial ready-to-use (RTU) setup, pharmaceutical companies and
Contract Manufacturing Organizations (CMOs) can benefit from
reduced operational risks, enhanced flexibility and efficiency, and
lower waste. RTU technology can help streamline processes, increase
productivity, and thus lower total cost of ownership (TCO) while
reducing contamination risks and easing EU GMP Annex 1
compliance.
Pharmaceutical companies, CMOs and CDMOs opting for ready-to-use
containers also can benefit from higher-quality products, which
helps minimize the release of glass particles and risks of breakage
or rejection while preserving the drug inside throughout its entire
life cycle.
Open expert platform for RTU industry standard
Additionally, the market is driving investment in advanced
aseptic filling technologies due to increasing demand for
injectable medicines and regulatory pressure to meet safety
standards. In this context, the Alliance for RTU aims to create an
expert platform open to other industry players to help industry
manufacturers learn about the key benefits of RTU processes and
products and to better evaluate investments for transitioning to
efficient filling systems and meeting their unique needs from
clinical applications to widespread commercial use.
“RTU vials and cartridges represent a significant advancement in
product quality, offering enhanced reliability and efficiency in
pharmaceutical processes. This alliance allows us to highlight
further how RTU solutions elevate standards across the industry,
ensuring safer and more effective delivery of medications to
patients worldwide," said Franco Stevanato, CEO at Stevanato
Group.
“The shift towards ready-to-use vials and cartridges reflects a
collective industry move to advance quality and efficiency in
aseptic filling processes and this alliance shows readiness by
expanding capacity and thereby supporting this market trend,” said
Andreas Reisse, CEO at SCHOTT Pharma. “Ready-to-use solutions can
reduce complexities and better meet the stringent requirements of
modern pharmaceutical production.”
"As an industry, we are fully prepared for the transition to RTU
vials and cartridges”, said Lukas Burkhardt, Member of the
Management Board of Gerresheimer AG. “With recent advancements, RTU
processing is now a mature technology which will improve our
customers operations in terms of efficiency, cost and time to
market."
The Alliance for RTU will be officially presented at the CPHI in
Milan on October 8 during a dedicated event at the tradeshow
fairground. For more information, visit
www.alliance-for-rtu.com.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: www.stevanatogroup.com.
About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and
a global partner to the pharma, biotech, and cosmetics industries.
The company offers a comprehensive portfolio of pharmaceutical
containment solutions, drug delivery systems and medical devices as
well as solutions for the health industry. The product range
includes digital solutions for therapy support, medication pumps,
syringes, pens, auto-injectors and inhalers as well as vials,
ampoules, tablet containers, infusion, dropper and syrup bottles,
and more. With 35 production sites in 16 countries in Europe,
America and Asia, Gerresheimer has a global presence and produces
locally for regional markets. With around 12,000 employees, the
company generated revenues of around €2bn in 2023. Gerresheimer AG
is listed in the MDAX on the Frankfurt Stock Exchange (ISIN:
DE000A0LD6E6).
www.gerresheimer.com
About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma designs
solutions grounded in science to ensure that medications are safe
and easy to use for people around the world. The portfolio
comprises drug containment solutions and delivery systems for
injectable drugs ranging from prefillable glass and polymer
syringes to cartridges, vials, and ampoules. Every day, a team of
over 4,600 people from over 60 nations works at SCHOTT Pharma to
contribute to global healthcare. The company is represented in all
main pharmaceutical hubs with 16 manufacturing sites in Europe,
North and South America, and Asia. With over 1,000 patents and
technologies developed in-house and a state-of-the-art R&D
center in Switzerland, the company is focused on developing
innovations for the future. SCHOTT Pharma AG & Co. KGaA is
headquartered in Mainz, Germany and listed on the Frankfurt Stock
Exchange as part of the SDAX. It is part of SCHOTT AG, which is
owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT
Pharma is committed to sustainable development for society and the
environment and has the strategic goal of becoming climate-neutral
by 2030. Currently, SCHOTT Pharma has over 1,800 customers
including the top 30 leading pharma manufacturers for injectable
drugs and generated revenue of EUR 899 million in the fiscal year
2023. Further information at www.schott-pharma.com.
Forward-Looking Statements
This press release may include forward-looking statements. The
words “aims”, “”increase”, “lower”, “ is driving”, “increasing”,
“create”, “move”, “expanding”, “advance”, “can”, “will”, and
similar expressions (or their negative) identify certain of these
forward-looking statements. These forward-looking statements are
statements regarding the Company's intentions, beliefs or current
expectations concerning, among other things, the investments the
Company expects to receive, the expansion of manufacturing
capacity, the Company’s plans regarding its presence in the U.S.
and other markets, business strategies, the Company’s capacity to
meet future market demands and support preparedness for future
public health emergencies, and results of operations. The
forward-looking statements in this press release are based on
numerous assumptions regarding the Company’s present and future
business strategies and the environment in which the Company will
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward looking
statements. Many of these risks and uncertainties relate to factors
that are beyond the Company's ability to control or estimate
precisely, such as future market conditions, currency fluctuations,
the behavior of other market participants, the actions of
regulators and other factors such as the Company's ability to
continue to obtain financing to meet its liquidity needs, changes
in the political, social and regulatory framework in which the
Company operates or in economic or technological trends or
conditions. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. Except as required by law, the company
assumes no obligation to update any such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240926050295/en/
Media Stevanato Group media@stevanatogroup.com Cassie Gonzalez:
stevanatoUS@teamlewis.com
Investor Relations Stevanato Group Lisa Miles:
lisa.miles@stevanatogroup.com
Media Gerresheimer AG Jutta Lorberg Head of Corporate
Communication T +49 211 6181 264 jutta.lorberg@gerresheimer.com
Investor Relations Gerresheimer AG Guido Pickert Vice President
Investor Relations T +49 152 900 14145
gerresheimer.ir@gerresheimer.com
Media SCHOTT Pharma Joana Kornblum Tel.: +49 151/29223552
E-Mail: joana.kornblum@schott.com
Investor Relations SCHOTT Pharma Jasko Terzic, CFA E-Mail:
ir.pharma@schott.com
Stevanato (NYSE:STVN)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Stevanato (NYSE:STVN)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
